OPuS-2 is an 12 week study of BCX4161, an oral kallikrein inhibitor being studied for prevention of HAE attacks in patients with Type I and II HAE. This study is currently open to enrolling patients in the US, UK, and Germany, with planned clinical trial locations in Belgium, Canada, Hungary, Italy and France.
If you are interested in learning more about the study, please see https://clinicaltrials.gov/ct2/show/NCT02303626?term=BCX4161&rank=3 and contact HAEi or your country’s HAE patient organization representative. (Source BioCryst Pharmaceuticals Inc.)
